文献速递白血病

伴胚系CEBPA突变家族性急性髓系白血病的家系调查与临床分析

[Investigation and clinical analysis of a family with germline CEBPA mutations in acute myeloid leukemia].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2020-01-01

该研究调查一个伴胚系CEBPA突变AML家系的临床特征与转归,共10人诊断为急性白血病,中位发病年龄9岁,6例死亡;基因测序发现5例携带CEBPA TAD p.G36Afs*124突变,其中4例确诊AML、1例随访未发病。结论提示该病多见于儿童及青壮年,外显率完全或接近完全,积极治疗大多预后良好。

要点

  • 伴胚系CEBPA突变家族性AML多发生于儿童及青壮年,中位发病年龄9岁。
  • 该家系中携带CEBPA TAD p.G36Afs*124突变者5例,4例确诊AML,外显率完全或接近完全。
  • 积极治疗(化疗联合造血干细胞移植)可使部分患者获得较好生存。

核心结论

  • 伴CEBPA基因突变的家族性AML多在儿童及青壮年期发病,具有完全或接近完全的外显率,通过积极治疗大多预后良好。

研究设计与样本

  • 调查一个伴CEBPA基因突变AML家系患者的发病年龄、临床特征、转归及预后并绘制家系谱。
  • 对先证者采集骨髓及口腔黏膜细胞,对有血缘关系的亲属采集外周血,通过基因测序技术检测基因突变。

主要发现

  • 该家系共10人诊断为AML,男4例、女6例,中位年龄9(3~48)岁。
  • 10例患者中6例死亡,其中4例未治疗,1例化疗后生存3年复发死亡,1例中药及支持治疗生存2年后死亡。
  • 4例患者生存,1例化疗后生存达15年,3例化疗联合造血干细胞移植至随访截止生存时间分别为6、9、28个月。
  • 对先证者及8名有血缘关系亲属基因测序,发现5例存在胚系CEBPA TAD p.G36Afs*124突变,其中4例确诊AML,1例随访至今未发病。

关键数值与推荐

  • 胚系CEBPA TAD p.G36Afs*124突变在受检家系成员中检出5例,其中4例确诊AML。

临床怎么用

  • 对家族性AML患者应进行胚系CEBPA基因检测并开展家系筛查。
  • 携带胚系CEBPA突变者需长期随访,积极治疗可能获得良好预后。

局限性

  • 本文为单家系调查,样本量有限,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the clinical characteristics, etiology, and prognosis of familial acute myeloid leukemia (AML) with germline CEBPA mutation and improve the understanding of familial leukemia. Methods: The age of onset, clinical characteristics, outcome, and prognosis of a family of patients with AML were investigated, and the family tree of the cases was displayed. Bone marrow and oral mucosal cells were collected from the proband, and peripheral blood was collected from the relatives of the proband. Gene mutation was detected by gene sequencing technology. Results: A total of 10 patients in this family were diagnosed with acute leukemia, including 4 males and 6 females, with a median age of 9 (3-48) years. Of the 10 patients, six died. Among them, 4 patients did not receive treatment, 1 patient survived 3 years after chemotherapy and died of relapse, and one patient died 2 years after receiving traditional Chinese medicine and supportive treatment. Four patients are alive. One patient has survived 15 years through chemotherapy, and three patients have survived with chemotherapy combined with hematopoietic stem cell transplantation, and the survival time was 6, 9, and 28 months at the end of follow-up. Gene sequencing was performed on proband and 8 relatives of the proband, and 5 were found to have the germline CEBPA TAD p.G36Afs*124 mutation. Among the 5 individuals with confirmed CEBPA mutation, 4 were diagnosed with AML, and 1 had not developed disease during follow-up. Conclusion: AML with germline CEBPA gene mutation mostly occurs in children and young adults, with complete or nearly complete penetrance. With active treatment, most of the patients have a favorable prognosis. 目的: 探讨伴CEBPA基因突变的家族性急性髓系白血病(AML)的临床特征、病因及转归,提高对家族性白血病的认识。 方法: 调查一个伴CEBPA基因突变AML家系患者的发病年龄、临床特征、转归及预后并绘制家系谱。对先证者采集骨髓及口腔黏膜细胞,与先证者有血缘关系的亲属,采集外周血,通过基因测序技术检测基因突变。 结果: 该家系共有10人诊断为AML,其中男4例,女6例,中位年龄9(3~48)岁。10例患者中,6例死亡,其中4例未进行治疗,1例患者化疗后生存3年复发死亡,1例采取中药及支持治疗生存2年后死亡。4例患者生存,1例接受化疗患者生存达15年,3例患者接受化疗联合造血干细胞移植,至随访截止,生存时间分别为6、9、28个月。对先证者及8名与先证者有血缘关系的亲属进行基因测序,发现5例存在胚系CEBPA TAD p.G36Afs*124突变,其中4例确诊为AML,1例随访至今未发病。 结论: 伴CEBPA基因突变的家族性AML多在儿童及青壮年期发病,具有完全或接近完全的外显率,通过积极治疗,大多预后良好。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zhang JP, Lin D, Wang SC, et al. [Investigation and clinical analysis of a family with germline CEBPA mutations in acute myeloid leukemia]. Zhonghua Xue Ye Xue Za Zhi. 2020. PMID: 33445848. doi:10.3760/cma.j.issn.0253-2727.2020.12.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。